How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Tissue and Organ Transplantation Market
- By Organ Type: Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Pancreas Transplant, Intestinal Transplant
- By Tissue Type: Corneal Transplant, Skin Grafting, Bone Grafting, Heart Valve Transplant, Vascular Tissue Transplant, Cartilage Transplant
- By Transplant Procedure: Autograft, Allograft, Xenograft, Islet Cell Transplantation, Stem Cell Transplantation
- By Source of Donor: Deceased Donor, Living Donor, Cadaveric Donor, Paired Kidney Exchange
- By End User: Hospitals, Specialized Transplant Centers, Ambulatory Surgical Centers, Research Institutes
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Kidney Transplant leads By Organ Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 306 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Tissue and Organ Transplantation Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Organ Type 6
Tissue Type 6
Transplant Procedure 5
Source of Donor 4
End User 4
Companies profiled
Organ Recovery Systems
TransMedics
XVIVO Perfusion
Medtronic
ThermoGenesis Holdings
Paragonix Technologies
OrganOx
LifeNet Health
Miromatrix Medical
Aziyo Biologics
CryoLife
Bridge to Life
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Organ Recovery Systems
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →TransMedics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →XVIVO Perfusion
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ThermoGenesis Holdings
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Paragonix Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →OrganOx
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →LifeNet Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Miromatrix Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Aziyo Biologics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →CryoLife
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Bridge to Life
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Organovo
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Organovo Holdings
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cytograft Tissue Engineering
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,641M by 2033 · 11.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Kidney Transplant51.2
- Liver Transplant6.0
- Heart Transplant10.5
- Lung Transplant11.8
- Pancreas Transplant5.4
- Intestinal Transplant15.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,081M → $2,275M · 9.7%
Europe$753.6M → $1,577M · 9.7%
Asia Pacific$688.1M → $1,591M · 11.1%
Latin America$425.9M → $964.2M · 10.8%
Middle East and Africa$327.6M → $799.4M · 11.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.122026
11.132027
11.132028
11.152029
11.172030
11.182031
11.202032
11.212033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Organ Recovery Systems22.8
- TransMedics13.1
- XVIVO Perfusion6.6
- Medtronic10.8
- ThermoGenesis Holdings7.4
- Paragonix Technologies11.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Organ Type18.1%
Tissue Type18.3%
Transplant Procedure34.7%
Source of Donor12.8%
End User16.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.6
- Europe21.9
- Asia Pacific22.1
- Latin America13.4
- Middle East and Africa11.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Organ Recovery Systems | 86 | 95 | 76 | 95 | 81 | 92 | 88 |
| TransMedics | 79 | 80 | 92 | 71 | 77 | 92 | 82 |
| XVIVO Perfusion | 66 | 83 | 66 | 75 | 82 | 79 | 75 |
| Medtronic | 71 | 60 | 65 | 74 | 59 | 80 | 68 |
| ThermoGenesis Holdings | 60 | 76 | 77 | 53 | 59 | 51 | 63 |
| Paragonix Technologies | 63 | 46 | 46 | 66 | 58 | 66 | 58 |
| OrganOx | 43 | 44 | 62 | 55 | 61 | 43 | 51 |
| LifeNet Health | 56 | 45 | 60 | 56 | 48 | 41 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Organ Recovery Systems
- TransMedics
- XVIVO Perfusion
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Organ Recovery Systems | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| TransMedics | ◐ | ◐ | ✓ | ◐ | ✓ | ✓ |
| XVIVO Perfusion | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Medtronic | ✓ | − | ◐ | ✓ | ◐ | ◐ |
| ThermoGenesis Holdings | − | ✓ | ◐ | ◐ | ◐ | − |
| Paragonix Technologies | − | − | − | ✓ | − | ◐ |
| OrganOx | − | − | ◐ | − | ◐ | − |
| LifeNet Health | − | ◐ | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Organ Recovery Systems88
2TransMedics82
3XVIVO Perfusion75
4Medtronic68
5ThermoGenesis Holdings63
6Paragonix Technologies58
7OrganOx51
8LifeNet Health51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Organ Recovery SystemsTransMedics
Challenger2
Strong scale, closing on the leaders.
XVIVO PerfusionMedtronic
Contender2
Focused players with pockets of strength.
ThermoGenesis HoldingsParagonix Technologies
Niche2
Specialists in a single segment or region.
OrganOxLifeNet Health
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Organ Type in North America, then scale across Tissue and Organ Transplantation Market — a $565M beachhead inside a $10.2B market.
Beachhead (SOM)$565Mobtainable near-term
Serviceable (SAM)$3.63Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Kidney Transplant
Best fit — highest urgency & budget in Organ Type.
Economic buyer80 fit
Liver Transplant
Strong fit — clear ROI and a fast path to value.
End user69 fit
Heart Transplant
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Organ Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Tissue Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Transplant Procedure
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve21%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Organ Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Tissue and Organ Transplantation Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified25%
Evaluation14%
Closed-won6%
$9.8KCAC
$58KLTV
6.0:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Tissue and Organ Transplantation Market is a resilient opportunity — $6.97B by 2033, compounding at 4.7%.
TAM · 2025$4.85Btoday
TAM · 2033$6.97Bforecast
CAGR4.7%2027–2033
Cumulative$52.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.97BTotal addressable market
SAM$2.70BServiceable available market
SOM$576MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.7% CAGR
Demand compounds through 2033, outpacing GDP across Organ Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Organ Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.97BLarge & growingTAM by 2033 at 4.7% CAGR
$2.70BServiceable nowreachable with today’s model
$576MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.44BBear3.0% CAGR
$6.97BBase4.7% CAGR
$8.93BBull6.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Tissue Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Tissue and Organ Transplantation Market — a $1.47B market by 2033. Plan: grow share from 9.1% to 14.8%.
Market size · 2033$1.47Btotal addressable
Market CAGR6.4%2027–2033
Target share14.8%from 9.1% today
Revenue ambition$218Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 14.8% | Behind |
| Revenue | $134M | $218M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 35.8% | 41.4% | At risk |
| Customer retention | 92.0% | 93.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Organ Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Tissue Type capability
A defensible second engine — invest in Tissue Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Organ Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Tissue Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $23M capacity & capability investment
- Greenlight bolt-on M&A in Tissue Type
- Authorise North America expansion plan
- Fund R&D program for Organ Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Tissue and Organ Transplantation Market conversation — a $4.84B market you can size, segment and defend in minutes.
Market size · 2033$4.84Btotal opportunity
Growth4.2%CAGR to 2033
Addressable buyers1,561+accounts in scope
Typical ROI5.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Organ Type
Goal Grow share in Organ Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.3×return on cost, year one
< 3 mopayback period
$72K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Organ Recovery SystemsTransMedicsXVIVO PerfusionMedtronicThermoGenesis HoldingsParagonix TechnologiesOrganOxLifeNet Health+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Tissue and Organ Transplantation Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Tissue and Organ Transplantation Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Tissue and Organ Repair and Regeneration 3D Printing Products Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportTislelizumab Injection Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportTiropramide HCL Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportTirofiban Hydrochloride Monohydrate Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportTirofiban Hydrochloride Concentrated Solution for Injection Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportTirofiban Hydrochloride API Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportTIRF Microscopes Market
Market size, share, segmentation and regional forecast.
$642M market · 2025 base year
View reportTIRF Imaging Microscopes Market
Market size, share, segmentation and regional forecast.
$474M market · 2025 base year
View reportTiratricol Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportTip Foam Swab Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportTip-enhanced Raman Spectroscopy (TERS) Equipment Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportTip-based Automated Liquid Handling Workstation Market
Market size, share, segmentation and regional forecast.
$345M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.